Multimorbidity in Acute Coronary Syndrome

Multimorbidity (the presence of multiple long-term conditions) increases the complexity of management decisions for patients presenting with acute coronary syndrome (ACS). The purpose of this study was to ascertain the prevalence of multimorbidity in ACS and assess its impact on clinical management...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JACC. Advances (Online) Ročník 4; číslo 8; s. 102006
Hlavní autoři: Batty, Jonathan A., del Toro, Tamara, Drayton, Daniel J., Booth, Eleanor, Anik, Evrim, Sturley, Charlotte, Brown, Benjamin C., Kearney, Mark T., Hall, Marlous
Médium: Journal Article
Jazyk:angličtina
Vydáno: Elsevier Inc 01.08.2025
Témata:
acute coronary syndrome
aging
Cardiovascular
comorbidity
multimorbidity
myocardial infarction
RR
myocardial infarction
JBI Checklist
multimorbidity
ACS
NSTE
acute coronary syndrome
comorbidity
MACE
PCI
STEMI
LTC
aging
CABG
MI
BMI
percutaneous coronary intervention
major adverse cardiovascular events
Joanna Briggs Institute Critical Appraisal Checklist
body mass index
coronary artery bypass graft
relative risk
ST-segment elevation myocardial infarction
long-term condition
non–ST-segment elevation
ISSN:2772-963X, 2772-963X
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Multimorbidity (the presence of multiple long-term conditions) increases the complexity of management decisions for patients presenting with acute coronary syndrome (ACS). The purpose of this study was to ascertain the prevalence of multimorbidity in ACS and assess its impact on clinical management and outcomes. Medline, Web of Science, Embase, and Cochrane were searched to July 2024 for studies that reported: 1) the prevalence of multimorbidity in patients with incident ACS or 2) ACS management and/or clinical outcomes, stratified by multimorbidity status. Random-effects meta-analysis was performed to calculate pooled summary statistics and was supported by narrative synthesis. Overall, 41 studies were included. Those at low risk of bias (23 studies; npooled = 9,227,657) demonstrated a pooled prevalence of multimorbidity of 46.6% (95% CI: 38.9%-54.2%). Study-level determinants of prevalence included study setting (high-income: 48.5% [40.5%-56.5%] vs low- to middle-income countries: 35.3 [30.5%-40.3%]); P = 0.006) and the number of conditions in the per-study definition of multimorbidity (R2 = 79.6%; P < 0.001). Individual-level determinants of multimorbidity included advanced age, non–ST-segment elevation presentation, previous cardiac procedures, and greater body mass index. Multimorbidity was associated with reduced usage of invasive management and secondary preventative medication. Multimorbidity was associated with short-term mortality (≤30 day; relative risk [RR]pooled 95% CI: 1.43 [95% CI: 1.14-1.78]; P < 0.01) and longer-term mortality (>30 day; RRpooled: 1.87 [95% CI: 1.51-2.32]; P < 0.01). Each additional pre-existing long-term condition was associated with a 16% excess risk of mortality (RRpooled: 1.16 [95% CI: 1.06-1.26]; P < 0.01). Multimorbidity is common, associated with reduced use of guideline-directed therapies and adverse clinical outcomes in patients with ACS. (The prevalence of multimorbidity and its impact on clinical outcomes in patients with acute myocardial infarction: a systematic review and meta-analysis; CRD42023447122) [Display omitted]
ISSN:2772-963X
2772-963X
DOI:10.1016/j.jacadv.2025.102006